Valerie Mullins, PA
Physician Assistant · Greeneville, TNNPI 1760775365
Payments from drug & device makers
Across 619 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Pfizer$642
- GSK$633
- Boehringer Ingelheim$588
- Amgen$491
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,69799%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 146 | $1,430 |
| Novo Nordisk | 89 | $1,110 |
| Pfizer | 40 | $642 |
| GSK | 39 | $633 |
| Boehringer Ingelheim | 39 | $588 |
| Amgen | 39 | $491 |
| Lilly USA, LLC | 35 | $486 |
| Otsuka America Pharmaceutical, Inc. | 25 | $482 |
| Bayer | 13 | $239 |
| Axsome Therapeutics, Inc. | 12 | $212 |
| AstraZeneca | 13 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $179 |
| Dexcom, Inc. | 11 | $176 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $170 |
| Novartis | 10 | $155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $150 |
| Esperion Therapeutics, Inc. | 8 | $136 |
| Xeris Pharmaceuticals, Inc. | 7 | $120 |
| Mylan Specialty L.p. | 9 | $117 |
| Astellas Pharma US Inc | 3 | $116 |
| Exact Sciences | 7 | $110 |
| Lundbeck LLC | 5 | $107 |
| Sumitomo Pharma America, Inc. | 6 | $91 |
| Johnson & Johnson | 5 | $70 |
| Biohaven Pharmaceuticals, Inc. | 4 | $69 |
| Amarin Pharma, Inc. | 4 | $63 |
| Antares Pharma, Inc. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| UCB, Inc. | 1 | $37 |
| Ardelyx, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Viatris Specialty LLC | 1 | $15 |
| Merck | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$8,783 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $330,066 |
| EliquisApixaban | 324 | $219,142 |
| OzempicSemaglutide | 134 | $133,840 |
| JardianceEmpagliflozin | 158 | $119,664 |
| LinzessLinaclotide | 208 | $118,825 |
| JanuviaSitagliptin Phosphate | 113 | $79,643 |
| RybelsusSemaglutide | 62 | $75,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $73,330 |
| MounjaroTirzepatide | 59 | $64,889 |
| TrulicityDulaglutide | 51 | $60,615 |
| XareltoRivaroxaban | 68 | $49,271 |
| VraylarCariprazine Hcl | 28 | $40,358 |
| Spiriva HandihalerTiotropium Bromide | 64 | $32,937 |
| Spiriva RespimatTiotropium Bromide | 48 | $32,559 |
| Trokendi XrTopiramate | 11 | $31,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Eliquis | $642 | $549,208336 claims |
| Novo NordiskOzempic, Rybelsus | $1,110 | $209,214196 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $588 | $187,664265 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $1,430 | $186,624262 claims |
| Lilly USA, LLCMounjaro, Trulicity | $486 | $125,504110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $633 | $86,062121 claims |
| MerckJanuvia | $14 | $79,643113 claims |
| AstraZenecaSymbicort, Brilinta, Farxiga, Breztri Aerosphere | $190 | $58,214136 claims |
| Johnson & JohnsonXarelto | $70 | $49,27168 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $482 | $30,18118 claims |
| AmgenProlia | $491 | $24,03013 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $91 | $20,49532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Greeneville
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- Katherine RunyanKnoxville$156K
- John KramerNashville$125K
- Robert LaughertyAlcoa$122K
- Elisabeth BennettNashville$109K
- Whitney GatewoodMemphis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.